Publications

Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: Comparison with nonrandomized historical control individuals

Researchers undertook a retrospective, nonrandomized, interventional cohort analysis to assess visual outcomes after the administration of prophylactic intravitreal bevacizumab in patients with plaque-irradiated uveal melanoma.

Read More
MRV News
Melanoma News
Archive
Menu